New Option for Neuroendocrine Tumor Radiotherapy

We share important prescription drug information to help you stay informed about updates concerning particular prescription medicines.

Bexlutry Approved for Certain Neuroendocrine Tumors

On Sept. 14, 2026, the US Food and Drug Administration (FDA) approved Curium’s Bexlutry™ (lutetium Lu 177 dotatate) injection to treat adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut and hindgut neuroendocrine tumors. Bexlutry is a targeted radioligand therapy that binds to somatostatin receptors expressed on tumor cells and delivers localized radiation directly to tumors. The approval was granted through the FDA’s 505(b)(2) pathway as a radioligand equivalent to Novartis’ Lutathera® (lutetium Lu 177 dotatate). Formerly called gastrointestinal carcinoid tumors, GEP-NETs are a heterogeneous group of rare tumors arising in the gastrointestinal tract and pancreas. They are generally slow-growing and can be difficult to diagnose because symptoms often resemble those of other gastrointestinal conditions and vary based on the tumor’s location and hormone production. Approximately 25,000 new cases of GEP-NETs are diagnosed each year in the US. Bexlutry is administered as an intravenous (IV) infusion by healthcare professionals who are trained and authorized to give radiopharmaceuticals in facilities equipped to minimize exposure to radiation. The recommended dose is 7.4 GBq (200 mCi) once every eight weeks for four cycles. Here is the prescribing information.

FDA Approves First PET Imaging Agent for Assessing Glioma Progression

On Sept. 14, 2026, the FDA approved Telix Pharmaceuticals’ Pixclara® (floretyrosine F 18, or 18F-FET), an IV positron emission tomography (PET) imaging radiopharmaceutical indicated to differentiate recurrent or progressive glioma from treatment-related changes, in conjunction with other diagnostic evaluations, in adults and pediatric patients aged one month and older. Following surgery, radiation, or other therapies, conventional imaging such as MRI can make it difficult to determine whether a tumor is returning or whether imaging changes are related to prior treatment, creating a significant challenge for clinicians. Pixclara, the first FDA-approved FET-PET imaging agent and the only FDA-approved radiopharmaceutical specifically for glioma imaging, targets amino acid transporters that are more active in tumor cells, providing information beyond standard imaging. The approval expands access to a technology already recommended in international clinical practice guidelines, including NCCN Guidelines®, and may help improve diagnostic confidence and treatment planning for the approximately 24,000 patients diagnosed with glioma in the United States each year. The announcement did not include launch timing or cost information. Here is the prescribing information.

Joenja Expands into Pediatrics as First Approved APDS Therapy for Children Aged 4-11 Years

On Sept. 11, 2026, the FDA approved Pharming Group’s Joenja® (leniolisib) tablets for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS) in children aged 4 to 11 years weighing at least 27kg. This expands its 2023 approval in patients aged 12 years and older and marks the first approval for this pediatric population. APDS is a rare, progressive primary immunodeficiency characterized by recurrent infections, immune dysfunction, and an increased risk of long-term complications. The pediatric approval was supported by a multinational, open-label phase III study in children aged 4 to 11 years that demonstrated improvements in two key markers of disease activity, reduced lymphadenopathy and increased naïve B cells, after 12 weeks of treatment. The safety profile was consistent with previous experience, with common side effects including abdominal pain, respiratory tract infection, diarrhea, headache, cough, nausea, rhinitis, and alopecia. No drug-related serious adverse events were reported. The recommended pediatric dose is 40mg, 50mg or 70mg orally twice daily, depending on body weight. Newly approved pediatric tablet strengths are expected to be available in October 2026. The updated prescribing information may be found here.

Ameluz Gains FDA Approval for Superficial Basal Cell Carcinoma

The FDA approved Biofrontera’s Ameluz® (aminolevulinic acid hydrochloride) topical gel, 10%, used in combination with the BF-RhodoLED® red-light lamp, for the treatment of superficial basal cell carcinoma (sBCC) in adults on Sept. 14, 2026. Ameluz was previously approved to treat actinic keratosis, a precancerous skin condition, and this approval expands its use to skin cancer. Basal cell carcinoma is the most common skin cancer in the United States, and the new indication makes Ameluz the first FDA-approved photodynamic therapy (PDT) for the treatment of skin cancer.PDT involves applying a light-sensitizing medication to the lesion and activating it with a specific wavelength of red light to selectively destroy cancerous cells while preserving surrounding tissue. Approval was supported by 66% of patients treated with Ameluz PDT achieving complete clinical and histological clearance of the target lesion compared with 5% of patients receiving placebo-PDT. Histological clearance was observed in 76% versus 19%, while complete clinical clearance of all target lesions occurred in 83% versus 21% of patients. The most common adverse events were application-site reactions consistent with the established safety profile of Ameluz PDT. The updated prescribing information is available here.

Imdelltra Label Update Shortens Monitoring Time for Initial Dose

The FDA approved an update to the prescribing information for Amgen’s Imdelltra® (tarlatamab-dlle) on Sept. 14, 2026, a bispecific T-cell engager indicated for adults who have extensive-stage small cell lung cancer (ES-SCLC) whose disease has progressed following platinum-based chemotherapy. The label update reduces the recommended monitoring period after the first two infusions from 22 to 24 hours to 6 to 8 hours while maintaining requirements for next-day follow-up assessments and proximity to an appropriate healthcare setting for 48 hours after treatment due to the risk of cytokine release syndrome (CRS) and neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome (ICANS). Here is the updated prescribing information.

FDA Approves Two New Belotero Fillers for Midface Volume Restoration and Lip Enhancement

The FDA approved two new hyaluronic acid (HA) fillers from Merz Aesthetics’ on Sept. 14, 2026. Belotero Volume® (+) is indicated to improve volume deficits in the midface and correct midface contour deficiencies in adults aged 22 years and older. In comparison, Belotero Intense® (+) is indicated to temporarily add volume and improve lip fullness in adults older than 21 years. Belotero Balance® (+) was previously approved to correct moderate-to-severe facial wrinkles and folds. Both products use Merz’s proprietary Cohesive Polydensified Matrix (CPM®) gel technology, which is designed to integrate with surrounding tissue and support natural-looking results. Commercial availability is anticipated on Oct. 14, 2026, for Belotero Volume (+) and Dec. 1, 2026, for Belotero Intense (+). Here is the prescribing information for Belotero Volume, and Belotero Intense.

FDA Approves Kerendia for Chronic Kidney Disease Associated with Type 1 Diabetes

On Sept. 17, 2026, the FDA approved an expanded indication for Kerendia® (finerenone – Bayer) oral tablets to reduce urinary albumin-to-creatinine ratio (UACR), a surrogate marker reasonably likely to predict slowing of kidney disease progression, in adults who have chronic kidney disease (CKD) associated with type 1 diabetes. Finerenone is a selective nonsteroidal mineralocorticoid receptor antagonist that reduces inflammation and fibrosis in the kidneys. Approval was based on the phase 3 FINE-ONE trial, in which finerenone achieved a 25% greater reduction in UACR versus placebo at 6 months. The recommended dose is 10mg or 20mg orally once daily based on eGFR and serum potassium, with titration to 20mg daily after four weeks as appropriate. Common adverse reactions include hyperkalemia, hypotension, and hyponatremia. Serious warnings include hyperkalemia and worsening renal function; Kerendia is contraindicated with strong CYP3A4 inhibitors, adrenal insufficiency, and hypersensitivity to the product. Here is the updated prescribing information.

Ibtrozi Label Updated with Longer Duration-of-Response Data

On Sept. 16, 2026, the FDA approved a supplemental New Drug Application (sNDA) for Ibtrozi® (taletrectinib – Nuvation Bio), an oral, central nervous system-active ROS1 tyrosine kinase inhibitor indicated for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). The updated prescribing information incorporates longer-term efficacy data from the phase II TRUST-I and TRUST-II studies, including a median duration of response of 49.7 months in tyrosine kinase inhibitor-naïve patients enrolled in TRUST-I after a median follow-up of 51 months. The supplemental approval included an additional 14 months of follow-up data from the pivotal studies. The approved indication and safety sections were unchanged, and no new safety signals were identified with longer follow-up. The recommended dosage remains 600mg orally once daily on an empty stomach, with no food for at least 2 hours before and 2 hours after administration, until disease progression or unacceptable toxicity. The most common adverse reactions include diarrhea, nausea, vomiting, dizziness, rash, constipation, and fatigue. The updated prescribing information may be found here.